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The number of older dialysis patients is increasing in many countries. For example, the trend is linked to the increase in
the dialysis patients 70 years of age and over in Japan. Older dialysis patients often experience deteriorating physical
and psychological functions, and special consideration for older patients has been focused on improving or preventing
such deteriorations. On the other hand, from the standpoint of clinical studies, the distribution of clinical parameters,
clinical outcomes, and their associations of older dialysis patients differ from those of younger patients. Moreover, they
exhibit heterogeneous phenotypes. Health age may be more important than the chronological age in considering
older patients. Since the age is the most powerful predictor of survival, clinical interventions might have little benefit
on the very old dialysis patients. Therefore, maintaining the quality of life or activity of daily living might surpass
survival regarding the goal of management of very old dialysis patients. Above all, individualized management
according to the heterogeneity or health age are necessary for the older dialysis patients. Future clinical studies of
older dialysis patients are needed for the better understanding of this population.
Keywords: Altered risk factor pattern, Clinical parameter, Clinical outcome, Distribution, Health age, Heterogeneity,
Individualized management, Older dialysis populationBackground
The older dialysis populations are expanding throughout
the world. The increase in the older dialysis population
can be attributed to increasing in the population 70 years
of age and over in Japan (Fig. 1) [1]. Data from the
United States Renal Data System (USRDS) show a
similar trend in the dialysis population in the USA [2].
The proportion of older dialysis patients is even larger in
other countries. The Dialysis Outcome and Practice
Patterns Study (DOPPS) showed that nearly half of the
dialysis patients in Belgium are 75 years old or more [3].
The older people have many problems and issues. They
experience deteriorating physical function, for example,
sarcopenia, protein-energy wasting, frailty, and visual or
hearing loss. They experience deterioration of psychological
or psychiatric conditions. These conditions relate closely to
each other. Frailty can be associated with the impaired* Correspondence: hanafusa@twmu.ac.jp
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[4] as well as among the general population [5]. They can
become a vicious cycle to be broken. They may also suffer
from socio-economic difficulties. This malnutrition-
cachexia-relating syndrome, or geriatric syndrome, has
been reported to associate with worse clinical outcomes
[6–9]. The syndrome can include sarcopenia, wasting, and
frailty. Sarcopenia focuses on the muscles of the patients,
which encompasses muscle mass, strength, and gait speed
[10, 11]. Wasting indicates the reduction of visceral pro-
teins, body mass, muscle mass, and dietary intake [12].
Hereinafter, we refer to the reduction of physical compo-
nent as wasting. On the other hand, frailty is wider meaning
and the scope covers psychological, psychiatric, and socio-
economic conditions as well as physical conditions [13, 14].
We will refer to the deterioration of the various functions
of the patients not limited to physical components as frail
or frailty. Withdrawal or withholding of dialysis treatment
is a major concern among older dialysis patients.
Older dialysis patients have specific issues from the
standpoint of clinical studies or trials. Clinical studiesle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Trends of the proportions of patients by age group in the Japanese dialysis population. The numbers of dialysis patients have increased
over more than the past 30 years. The increase can be attributed to the increase in the number of patients with 70 years of age and over, at least
during the past ten years. Adopted from reference [1] with permission
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clinical parameters and outcomes. In this sense, the older
population can differ from the younger counterparts in all
these parameters which are essential for clinical studies,
namely the distribution of clinical parameters, outcomes
in both quality and quantity, and the association between
clinical parameters and outcomes (Fig. 2). Moreover, there
is no consensus definition of the term “older population.”
Older phenotype might be more important for older pa-
tients, and the phenotype can relate to the heterogeneity
of the population. In this review, we discuss these issues
concerning older dialysis population.Differences between older and younger dialysis
patients
The distribution of clinical parameters
The distributions of clinical parameters sometimes differ
across age groups. Figure 3 shows the distributions of
several clinical parameters obtained from the Japanese
Society for Dialysis Therapy Renal Data Registry (JRDR)
by age groups [15]. The patients with the low values wereFig. 2 Essential components of clinical studies. The aim of observational,
clinical studies is to attempt to identify the associations between clinical
parameters and clinical outcomes. All these components of clinical
studies can differ in their distributions between the older population and
the younger populationprevalent among the older age groups for all parameters
presented in this figure.
Extracellular volume status is also known to differ be-
tween the older and younger dialysis populations. A study
based on the Korean registry investigated the bio-
impedance parameters of 90 chronic hemodialysis patients
and found that their extracellular water to total body water
ratios, which are proxies for overhydration, correlated posi-
tively with the ages of the patients. Thus, older patients
may be more likely to experience overhydration [16].
On the other hand, these changes in the distribution of
clinical parameters have been confirmed by the studies
that adjusted for the patient characteristics. Lertdumron-
gluk et al. investigated chronic kidney disease-mineral
bone disorder (CKD-MBD) management across age
groups in a cohort of 107,817 patients who were receiving
their dialysis treatment at DaVita. They found that the
odds of developing hyperphosphatemia were lower in the
older population, but the odds of developing hypopho-
sphatemia were higher in the same population. Thus, the
distribution of serum phosphate levels can differ across
age groups even after adjustments for covariates [17].
Differences in clinical outcomes
Many studies have demonstrated that older dialysis pa-
tients are more likely to experience worse outcomes
than younger patients. This can be partially based on the
shorter life expectancy of the older general population.
Figure 4 demonstrates the comparison of the life expect-
ancy between the dialysis population and the general
population that was investigated in JRDR database. The














































































Age (years) Age (years)
Serum Albumin (g/dl) Serum Creatinine (mg/dl)
Serum Phosphate (mg/dl) Serum Total Cholesterol (mg/dl)
n=10,182 38,558 101,602 72,348 n=10,101 38,182 100,605 71,543
n=9,999 37,795 99,720 70,973 n=7,719 30,662 81,454 53,733
n=10,171 38,484 101,229 71,942 28,808 76,265 54,263n=7,601
Fig. 3 Distributions of the clinical parameters by age group. The distributions of clinical parameters are shown according to age group. The
patients with lower values were more prevalent than younger patients regarding all the clinical parameters shown in this figure. This figure was
reproduced from reference [15]
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compared to the younger population. Interestingly, the
ratios of the life expectancy of the dialysis population to
that of the general population were almost 50% irre-
spective of the age groups of the patients [18]. The fact
indicates that the shorter life span of the older dialysis
patients is due to the shorter life expectancy of the older
general population.
The results of a study that investigated the effects of the
older age in the DOPPS cohort showed that the group of
patients 75 years of age and over had higher mortality
rates than the group under 45 years of age in most of the
regions investigated [3]. Moreover, the distribution of the
causes of death might also differ across age groups. The
proportions of the patients died of cardiovascular disease
were smaller in the elderly group except in Japan [3].
JRDR database demonstrated that the proportion of the
patients died of cardiovascular disease were almost similar
in the elderly patients to the younger patients except forthe group of 45–59 years old, while the proportion that
died of infection was larger in the older groups (Fig. 5). A
similar result was obtained regarding the quality of life
(QOL). The older patients might experience poorer QOL
than the younger patients, especially based on the physical
component summary scores; although, the mental compo-
nent summary did not differ across the age groups [3]. Re-
garding QOL, such association can be controversial;
several studies demonstrated that the decline in QOL
scores among the older dialysis population was slower
than the younger patients [19, 20]. Although the associa-
tions between the age groups and QOL scores are not uni-
form and affected by the criteria investigated, many
studies demonstrated that age is one of the major determi-
nants of QOL and that the physical functioning in QOL
tended to be worse in the older population [21].
These results indicate that the distribution of clinical





Fig. 4 Life expectancy of the Japanese general population and dialysis population by age. The life expectancy by year were demonstrated
among the Japanese general (gray lines) and dialysis (black lines) population for male (a) and female (b). The ratios of life expectancy of dialysis
patients to the general population by sex (the black line, male; the gray line, female) were also demonstrated by age (c). The ratios were almost
uniform and about 50% irrespective of patients’ age. This figure was reproduced from reference [18]
Fig. 5 The breakdown of the causes of death by age groups. The
breakdown and proportion of the patients who died of CVD,
infection, and malignancy were demonstrated in black, gray, and
open bars, respectively. The proportions of CVD as a cause of death
were almost equal across age groups except for the group with 45–
59 years old. On the other hand, the patients who died of infection
were more prevalent in the older patients. Because the patients who
died of other causes of death were omitted, the proportions do not
sum up to 100%. The figure was produced from the data in
reference [15]. CVD, cardiovascular disease
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parameter values and outcomes
The aim of clinical studies is to attempt to identify the
association between clinical parameter values and
clinical outcomes that can serve as the basis for random-
ized control trials. Such changes in associations should
be considered even in daily clinical practice.
The association between gender and survival may dif-
fer across age groups, although somewhat controversial
[22]. A study based on the Canadian Organ Replacement
Registry investigated associations between gender and
all-cause mortality across age groups in a cohort of
28,971 incident chronic hemodialysis patients. This
study found that women had survival benefits over men
among young patients under 45 years of age, whereas
among the older patients 75 years of age and over,
women had a lower survival probability than men, even
after adjustment for covariates [23]. These results
showed that association between gender and survival
might differ across age groups.
Hemoglobin (Hb) levels are another example. We in-
vestigated the association between Hb levels and survival
across age groups in the Japan DOPPS cohort [24] and
found differences between the younger group and older
group. In the group with Hb levels in the 9–10 g/dl
range, only the younger group under 75 years of age had
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the 10–11 g/dl range (HR 1.46, 95% CI 1.07–2.00), but
the older population in the same Hb levels did not ex-
perience worse survival (HR 0.83, 95% CI 0.57–1.21).
Moreover, a significant interaction between Hb levels
and age groups was found in the group with Hb levels in
the 9–10 g/dl range (p = 0.044).
This result was confirmed by another study based on
the Korean cohort. This study found that only the youn-
ger group with Hb levels in the 9–10 g/dl range who
were under 65 years of age had a significantly higher
mortality risk than the group with Hb levels in the 10–
11 g/dl range (HR 4.78, 95% CI 1.81–12.62). On the
other hand, the older group did not have a significantly
worse outcome (HR 1.80, 95% CI 0.95–3.39); although,
the interaction between Hb levels and age groups was
marginally non-significant (p = 0.0526) [25].
The study mentioned above from DaVita investigated
the associations between serum phosphate levels and
mortality by age groups [17] and found a J-shaped or
U-shaped association between serum phosphate levels
and all-cause mortality in the crude models. On the
other hand, hypophosphatemia (serum phosphate
below 3.5 mg/dl) was associated with higher mortality
only in the 65 years of age over group after adjust-
ment for covariates, including for malnutrition-
inflammation complex syndrome, while hyperphosphate-
mia (serum phosphate above 5.5 mg/dl) was uniformly
associated with higher mortality risks across all age
groups [17].Another type of altered risk factor patterns
Risk-factor patterns have been reported to change as
chronic kidney disease (CKD) stages progress. More
specifically, the associations between clinical parameters
and outcomes found in the end-stage renal disease
(ESRD) population may differ from the patterns ob-
served in early stages of CKD or even in the general
population. Such alterations encompass body mass index
[26], body height [27, 28], blood pressure [29], and
serum cholesterol level [30]. These findings are called
“altered risk factor patterns” [31, 32] or “reverse epi-
demiology” [33]. These altered risk factor patterns
can be found in other disease conditions, including
congestive heart failure [34], cancer [35], acquired
immune deficiency syndrome [36], and even in the
older general population [37]. On the other hand, as
discussed above, associations between risk factors or
clinical parameters and clinical outcomes might
change again with advancing age even if the popula-
tion is confined to ESRD. Such change may be an-
other type of risk factor pattern alterations among
patients with kidney disease.Older populations are heterogeneous
Another problem is that older population is heterogeneous.
This fact also relates to the definition of older patients, be-
cause the cut-off age for older patients can be ambiguous
due to the heterogeneities in the health status among them.
The scheme shown in Fig. 6 illustrates the heterogeneity
of older dialysis patients. During the normal aging process,
actual or chronological age and age based on health status,
i.e., health age, are almost identical. Here, the health age is
a conceptual age by which we can consider a patient robust
or frail, and the health age can closely relate to the clinical
outcomes more than the actual or chronological age. How-
ever, the relationship between chronological age and health
age can vary among the patients. Patients who are consid-
ered frail have a higher health age than their chronological
age, while patients who are considered robust have a lower
health age than their chronological age. Importantly, the
disparities between chronological age and health age be-
come wider in older populations. Moreover, health age may
be more closely associated with outcomes than biological
age. Thus, patients can be classified as old or young by their
health age. Although Fig. 6 is only conceptual, the older
dialysis patients are more heterogenic than the younger pa-
tients in terms of the phenotypes of wasting or the geriatric
syndrome as discussed later. This concept can also be sup-
ported by clinical experiences in daily practice. The concept
should be confirmed, and the definition of the health age it-
self should be determined by future investigations.
We performed a preliminary study on heterogeneities in
the older dialysis population in the JRDR, the Japanese
Registry [38], by comparing the coefficients of variances of
clinical parameters with those of the 45–59 years of age
groups. The heterogeneities of the clinical parameters in-
dicating “wasting,” including creatinine generation rate,
serum levels of creatinine, and albumin exhibited large
heterogeneities. Therefore, these parameters might relate
to the frailty or robustness of the patients.
This study confirmed that the older population is hetero-
geneous, especially regarding clinical parameters related to
wasting. This finding was reinforced by the evidence that
protein-energy wasting is closely associated with worse out-
comes independent of the patient’s age [39–41]. The signifi-
cance of wasting in considering the well-being or outcomes
of the older patients requires further investigation. Activities
of daily living (ADL) or comorbidities can be the key issues
for an understanding of such heterogeneities among the
older patients or the health age. The older incident dialysis
patients tend to experience worse ADL assessed by Barthel
index [42, 43], and the lower ADL can be associated with
the worse outcome [43]. The comorbidities of the patients
also relate to the worse outcome even among the elderly pa-
tients who undergo dialysis treatments [44–46]. The patients
with wasting are vulnerable to complications leading to co-
morbidities, while the patients with multiple comorbidities
Fig. 6 Scheme of older dialysis patients and heterogeneities. Conceptually, two types of age expression can be considered in a single patient,
actual and chronological ages. The chronological age is usually used to determine the age of patients, while health age is a conceptual age and
it determines the phenotype of the patients. During the normal aging process, the two ages are identical. Patients are considered frail when their
health ages are higher than their actual ages. Importantly, the disparities or the heterogeneities across patients are wider in the older population
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relationship between wasting and comorbidities remains un-
clear because these relationships have been obtained
through observational studies. It is possible that interven-
tions against wasting can break the vicious cycle of wasting
and comorbidities.a
c
Fig. 7 Crude mortality rates according to primary diagnosis and the age at
primary diagnosis of end-stage renal disease and age at the start of dialysis
45–59, 60–74, and 75–89 years old in panels a, b, c, and d, respectively. Pri
are shown in black, dark gray, and pale gray, respectively. The differences in
figure was reproduced from reference [47]Appropriate goals for the management of older
dialysis patients
Age itself is still the most powerful predictor of survival;
although, wasting also has a substantial effect on survival.
Figure 7 indicates the survival rates by primary diagnoses of
the patients [47]. The survival rates were almost identicalb
d
the start of dialysis. Crude mortality rates are shown according to the
therapy. The age groups at the start of dialysis therapy were 30–44,
mary diagnoses of glomerulonephritis, nephrosclerosis, and diabetes
survival decreased as the age at the start of dialysis increased. This
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population. This fact suggests that therapeutic interventions
on the very old dialysis patients might be of little benefit.
Therefore, the goals of the management of such patients
could be improving the well-being, QOL, or ADL rather
than their survival. Of course, we should prioritize the
preferences of patients and their families or caregivers and
discuss the goals carefully and comprehensively in decision
making.
Conclusions
Older dialysis populations differ from younger dialysis
populations in the distributions of their clinical parame-
ters, clinical outcomes, and associations between them.
Moreover, there are great heterogeneities within older
populations, especially regarding wasting phenotypes, and
these heterogeneities require individualized managements.
Finally, individualized goals of dialysis management are
also necessary, especially for the very old population.
However, many points remain to be elucidated regarding
the management of older dialysis patients.
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